Global Neoantigen Cancer Vaccine Market, By Product (Personalized Neoantigen Vaccine, Off-the Shelf Neoantigen Vaccine), By Neoantigen Type (Synthetic Long Peptide (SLP), Nucleic Acid, Dendritic Cell, Tumor Cell), By Route of Administration (Intravenous,

Global Neoantigen Cancer Vaccine Market, By Product (Personalized Neoantigen Vaccine, Off-the Shelf Neoantigen Vaccine), By Neoantigen Type (Synthetic Long Peptide (SLP), Nucleic Acid, Dendritic Cell, Tumor Cell), By Route of Administration (Intravenous, Intramuscular, Transdermal, Others), By Cell (Autologous, Allogenic), By Technology (RNA Sequencing, Whole Genome Sequencing, HLA Typing), By Delivery Mechanism (Liposomes, Virosomes, Electroporation, Gene gun, Others), By Application (Lung, Melanoma, Gastrointestinal, Brain Cancer, Others), By Region, Competition, Forecast & Opportunities, 2026

Global neoantigen cancer vaccine market is projected to grow with a CAGR of 54.18% during the forecast period and is expected to reach USD1754.44 million by 2026. The key factors responsible for the growth of neoantigen cancer vaccine market include rapid innovations in technology as well as infrastructural developments in healthcare sector. Additionally, growing investments by the governing bodies and healthcare providers is another major factor that is anticipated to boost the growth of neoantigen cancer vaccine market across the globe in the coming years.

The global neoantigen cancer vaccine market is segmented based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, region, and company. Based on route of administration, the market can be segmented into intravenous, intramuscular, transdermal and others. Out of which, the intravenous segment is expected to dominate the market through 2026 and intramuscular is anticipated to be the fastest growing segment in the forecast period. This growth can be accredited to quick response as well as to the fact that drug dosage can be controlled easily. Along with that, intramuscular injections can be used rather than intravenous because some drugs cause irritation to veins when injected intravenously. This is expected to result in high growth of intramuscular route of administration segment in the coming years.

The application segment is further segregated into lung, melanoma, gastrointestinal, brain cancer, and others. The lung cancer segment is going to dominate the market in the forecast period as the neoantigen based immunotherapy of OSE Immunotherapeutics, which is in development for the Tedopi (OSE2101) neoantigen cancer vaccine is expected to launch in 2022. Tedopi (OSE2101), is used in the treatment of HLA-A2+ Lung cancer (NSCLC) patients. Currently, the vaccine is in phase III stage of clinical development.

Regionally, Asia Pacific neoantigen cancer vaccine market is expected to be the leading region over the forecast period due to the rising prevalence and incidence of cancer cases including lung cancer, melanoma, gastrointestinal, pancreatic cancer and other solid tumor indications.

Major players operating in the global neoantigen cancer vaccine market include OSE Immunotherapeutics SA, Gritstone bio, Inc., BioNTech SE, F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co., Inc., Moderna Inc., Avidea Technologies, Inc., Eli Lilly and Company, Vaccibody AS, Agenus Inc., Novogene Co., Ltd., ZIOPHARM Oncology Inc., ISA Pharmaceuticals B.V., BrightPath Biotherapeutics Co., Ltd., Vaximm AG, Medigene AG, Genocea Biosciences Inc., Advaxis, Inc., Nouscom AG, among others are the leading players operating in global neoantigen cancer vaccine market. The companies operating in the market across the globe are focusing more towards expanding their share in the market.

Years considered for this report:

Base Year: 2020

Estimated Year: 2022

Forecast Period: 2023-2026

Objective of the Study:

  • To analyze and forecast the market size of global neoantigen cancer vaccine market.
  • To classify and forecast global neoantigen cancer vaccine market based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, company and regional distribution from 2021 to 2026 and growth rate until 2026.
  • To identify drivers and challenges for global neoantigen cancer vaccine market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global neoantigen cancer vaccine market.
  • To conduct pricing analysis for global neoantigen cancer vaccine market.
  • To identify and analyze the profile of leading players operating in global neoantigen cancer vaccine market.
TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the new products, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global neoantigen cancer vaccine market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:
  • Neoantigen cancer vaccine manufacturers and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to neoantigen cancer vaccine
  • Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global neoantigen cancer vaccine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
  • Global Neoantigen Cancer Vaccine Market, By Product:
  • Personalized neo-antigen vaccine
  • Off-the shelf neoantigen vaccine
  • Global Neoantigen Cancer Vaccine Market, By Neoantigen Type:
  • Synthetic Long Peptide
  • Nucleic acid
  • Dendritic cell
  • Tumor cell
  • Global Neoantigen Cancer Vaccine Market, By Route of Administration:
  • Intravenous
  • Intramuscular
  • Transdermal
  • Others
  • Global Neoantigen Cancer Vaccine Market, By Cell:
  • Autologous
  • Allogenic
  • Global Neoantigen Cancer Vaccine Market, By Technology:
  • RNA Sequencing
  • Whole Genome Sequencing
  • HLA Typing
  • Global Neoantigen Cancer Vaccine Market, By Delivery Mechanism:
  • Liposomes
  • Virosomes
  • Gene gun
  • Electroporation
  • Others
  • Global Neoantigen Cancer Vaccine Market, By Application:
  • Lung
  • Melanoma
  • Gastrointestinal
  • Brain cancer
  • Others
  • Global Neoantigen Cancer Vaccine Market, By Region:
  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Singapore
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global neoantigen cancer vaccine market.

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order. Single User license will be delivered in PDF format without printing rights


1. Product Overview
2. Research Methodology
3. Clinical Trial Analysis
4. Executive Summary
5. Global Neoantigen Cancer Vaccine Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value & Volume
5.2. Market Share & Forecast
5.2.1. By Product (Personalized Neo-antigen Vaccine, Off-the Shelf Neoantigen Vaccine)
5.2.2. By Neoantigen Type (Synthetic Long Peptide (SLP), Dendritic Cell, Nucleic Acid, Tumor Cell)
5.2.3. By Route of Administration (Intravenous, Intramuscular, Transdermal, Others)
5.2.4. By Cell (Autologous, Allogenic)
5.2.5. By Technology (RNA Sequencing, Whole Genome Sequencing, HLA Typing)
5.2.6. By Delivery Mechanism (Liposomes, Virosomes, Electroporation, Gene gun and Others)
5.2.7. By Application (Lung, Melanoma, Gastrointestinal, Brain cancer, and Others)
5.2.8. By Company (2023)
5.2.9. By Region
5.3. Product Market Map
6. North America Neoantigen Cancer Vaccine Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value & Volume
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Neoantigen Type
6.2.3. By Route of Administration
6.2.4. By Cell
6.2.5. By Technology
6.2.6. By Application
6.2.7. By Country
6.3. Product Market Map
6.4. North America: Country Analysis
6.4.1. United States Neoantigen Cancer Vaccine Market Outlook
6.4.1.1. Market Size & Forecast
6.4.1.1.1. By Value
6.4.1.2. Market Share & Forecast
6.4.1.2.1. By Product
6.4.1.2.2. By Neoantigen Type
6.4.1.2.3. By Route of Administration
6.4.1.2.4. By Cell
6.4.1.2.5. By Technology
6.4.1.2.6. By Application
6.4.2. Canada Neoantigen Cancer Vaccine Market Outlook
6.4.2.1. Market Size & Forecast
6.4.2.1.1. By Value
6.4.2.2. Market Share & Forecast
6.4.2.2.1. By Product
6.4.2.2.2. By Neoantigen Type
6.4.2.2.3. By Route of Administration
6.4.2.2.4. By Cell
6.4.2.2.5. By Technology
6.4.2.2.6. By Application
6.4.3. Mexico Neoantigen Cancer Vaccine Market Outlook
6.4.3.1. Market Size & Forecast
6.4.3.1.1. By Value
6.4.3.2. Market Share & Forecast
6.4.3.2.1. By Product
6.4.3.2.2. By Neoantigen Type
6.4.3.2.3. By Route of Administration
6.4.3.2.4. By Cell
6.4.3.2.5. By Technology
6.4.3.2.6. By Application
7. Europe Neoantigen Cancer Vaccine Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value & Volume
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Neoantigen Type
7.2.3. By Route of Administration
7.2.4. By Cell
7.2.5. By Technology
7.2.6. By Application
7.2.7. By Country
7.3. Product Market Map
7.4. Europe: Country Analysis
7.4.1. Germany Neoantigen Cancer Vaccine Market Outlook
7.4.1.1. Market Size & Forecast
7.4.1.1.1. By Value
7.4.1.2. Market Share & Forecast
7.4.1.2.1. By Product
7.4.1.2.2. By Neoantigen Type
7.4.1.2.3. By Route of Administration
7.4.1.2.4. By Cell
7.4.1.2.5. By Technology
7.4.1.2.6. By Application
7.4.2. France Neoantigen Cancer Vaccine Market Outlook
7.4.2.1. Market Size & Forecast
7.4.2.1.1. By Value
7.4.2.2. Market Share & Forecast
7.4.2.2.1. By Product
7.4.2.2.2. By Neoantigen Type
7.4.2.2.3. By Route of Administration
7.4.2.2.4. By Cell
7.4.2.2.5. By Technology
7.4.2.2.6. By Application
7.4.3. United Kingdom Neoantigen Cancer Vaccine Market Outlook
7.4.3.1. Market Size & Forecast
7.4.3.1.1. By Value
7.4.3.2. Market Share & Forecast
7.4.3.2.1. By Product
7.4.3.2.2. By Neoantigen Type
7.4.3.2.3. By Route of Administration
7.4.3.2.4. By Cell
7.4.3.2.5. By Technology
7.4.3.2.6. By Application
7.4.4. Italy Neoantigen Cancer Vaccine Market Outlook
7.4.4.1. Market Size & Forecast
7.4.4.1.1. By Value
7.4.4.2. Market Share & Forecast
7.4.4.2.1. By Product
7.4.4.2.2. By Neoantigen Type
7.4.4.2.3. By Route of Administration
7.4.4.2.4. By Cell
7.4.4.2.5. By Technology
7.4.4.2.6. By Application
7.4.5. Spain Neoantigen Cancer Vaccine Market Outlook
7.4.5.1. Market Size & Forecast
7.4.5.1.1. By Value
7.4.5.2. Market Share & Forecast
7.4.5.2.1. By Product
7.4.5.2.2. By Neoantigen Type
7.4.5.2.3. By Route of Administration
7.4.5.2.4. By Cell
7.4.5.2.5. By Technology
7.4.5.2.6. By Application
8. Asia-Pacific Neoantigen Cancer Vaccine Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value & Volume
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Neoantigen Type
8.2.3. By Route of Administration
8.2.4. By Cell
8.2.5. By Technology
8.2.6. By Application
8.2.7. By Country
8.3. Product Market Map
8.4. Asia-Pacific: Country Analysis
8.4.1. China Neoantigen Cancer Vaccine Market Outlook
8.4.1.1. Market Size & Forecast
8.4.1.1.1. By Value
8.4.1.2. Market Share & Forecast
8.4.1.2.1. By Product
8.4.1.2.2. By Neoantigen Type
8.4.1.2.3. By Route of Administration
8.4.1.2.4. By Cell
8.4.1.2.5. By Technology
8.4.1.2.6. By Application
8.4.2. India Neoantigen Cancer Vaccine Market Outlook
8.4.2.1. Market Size & Forecast
8.4.2.1.1. By Value
8.4.2.2. Market Share & Forecast
8.4.2.2.1. By Product
8.4.2.2.2. By Neoantigen Type
8.4.2.2.3. By Route of Administration
8.4.2.2.4. By Cell
8.4.2.2.5. By Technology
8.4.2.2.6. By Application
8.4.3. Japan Neoantigen Cancer Vaccine Market Outlook
8.4.3.1. Market Size & Forecast
8.4.3.1.1. By Value
8.4.3.2. Market Share & Forecast
8.4.3.2.1. By Product
8.4.3.2.2. By Neoantigen Type
8.4.3.2.3. By Route of Administration
8.4.3.2.4. By Cell
8.4.3.2.5. By Technology
8.4.3.2.6. By Application
8.4.4. Australia Neoantigen Cancer Vaccine Market Outlook
8.4.4.1. Market Size & Forecast
8.4.4.1.1. By Value
8.4.4.2. Market Share & Forecast
8.4.4.2.1. By Product
8.4.4.2.2. By Neoantigen Type
8.4.4.2.3. By Route of Administration
8.4.4.2.4. By Cell
8.4.4.2.5. By Technology
8.4.4.2.6. By Application
8.4.5. South Korea Neoantigen Cancer Vaccine Market Outlook
8.4.5.1. Market Size & Forecast
8.4.5.1.1. By Value
8.4.5.2. Market Share & Forecast
8.4.5.2.1. By Product
8.4.5.2.2. By Neoantigen Type
8.4.5.2.3. By Route of Administration
8.4.5.2.4. By Cell
8.4.5.2.5. By Technology
8.4.5.2.6. By Application
8.4.6. Singapore Neoantigen Cancer Vaccine Market Outlook
8.4.6.1. Market Size & Forecast
8.4.6.1.1. By Value
8.4.6.2. Market Share & Forecast
8.4.6.2.1. By Product
8.4.6.2.2. By Neoantigen Type
8.4.6.2.3. By Route of Administration
8.4.6.2.4. By Cell
8.4.6.2.5. By Technology
8.4.6.2.6. By Application
9. South America Neoantigen Cancer Vaccine Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value & Volume
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Neoantigen Type
9.2.3. By Route of Administration
9.2.4. By Cell
9.2.5. By Technology
9.2.6. By Application
9.2.7. By Country
9.3. Product Market Map
9.4. South America: Country Analysis
9.4.1. Brazil Neoantigen Cancer Vaccine Market Outlook
9.4.1.1. Market Size & Forecast
9.4.1.1.1. By Value
9.4.1.2. Market Share & Forecast
9.4.1.2.1. By Product
9.4.1.2.2. By Neoantigen Type
9.4.1.2.3. By Route of Administration
9.4.1.2.4. By Cell
9.4.1.2.5. By Technology
9.4.1.2.6. By Application
9.4.2. Argentina Neoantigen Cancer Vaccine Market Outlook
9.4.2.1. Market Size & Forecast
9.4.2.1.1. By Value
9.4.2.2. Market Share & Forecast
9.4.2.2.1. By Product
9.4.2.2.2. By Neoantigen Type
9.4.2.2.3. By Route of Administration
9.4.2.2.4. By Cell
9.4.2.2.5. By Technology
9.4.2.2.6. By Application
9.4.3. Colombia Neoantigen Cancer Vaccine Market Outlook
9.4.3.1. Market Size & Forecast
9.4.3.1.1. By Value
9.4.3.2. Market Share & Forecast
9.4.3.2.1. By Product
9.4.3.2.2. By Neoantigen Type
9.4.3.2.3. By Route of Administration
9.4.3.2.4. By Cell
9.4.3.2.5. By Technology
9.4.3.2.6. By Application
10. Middle East and Africa Neoantigen Cancer Vaccine Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value & Volume
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Neoantigen Type
10.2.3. By Route of Administration
10.2.4. By Cell
10.2.5. By Technology
10.2.6. By Application
10.2.7. By Country
10.3. Product Market Map
10.4. MEA: Country Analysis
10.4.1. South Africa Neoantigen Cancer Vaccine Market Outlook
10.4.1.1. Market Size & Forecast
10.4.1.1.1. By Value
10.4.1.2. Market Share & Forecast
10.4.1.2.1. By Product
10.4.1.2.2. By Neoantigen Type
10.4.1.2.3. By Route of Administration
10.4.1.2.4. By Cell
10.4.1.2.5. By Technology
10.4.1.2.6. By Application
10.4.2. Saudi Arabia Neoantigen Cancer Vaccine Market Outlook
10.4.2.1. Market Size & Forecast
10.4.2.1.1. By Value
10.4.2.2. Market Share & Forecast
10.4.2.2.1. By Product
10.4.2.2.2. By Neoantigen Type
10.4.2.2.3. By Route of Administration
10.4.2.2.4. By Cell
10.4.2.2.5. By Technology
10.4.2.2.6. By Application
10.4.3. UAE Neoantigen Cancer Vaccine Market Outlook
10.4.3.1. Market Size & Forecast
10.4.3.1.1. By Value
10.4.3.2. Market Share & Forecast
10.4.3.2.1. By Product
10.4.3.2.2. By Neoantigen Type
10.4.3.2.3. By Route of Administration
10.4.3.2.4. By Cell
10.4.3.2.5. By Technology
10.4.3.2.6. By Application
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
13. Competitive Landscape
13.1. Competition Outlook
13.2. Players Profiled (Leading Companies)
13.2.1. OSE Immunotherapeutics SA
13.2.2. Gritstone bio, Inc.
13.2.3. BioNTech SE
13.2.4. F. Hoffmann-La Roche Ltd.
13.2.5. Pfizer Inc.
13.2.6. Merck & Co. Inc.
13.2.7. Moderna Inc.
13.2.8. Avidea Technologies, Inc.
13.2.9. Eli Lilly and Company
13.2.10. Vaccibody AS
13.2.11. Agenus Inc.
13.2.12. Novogene Co., Ltd.
13.2.13. ZIOPHARM Oncology Inc.
13.2.14. ISA Pharmaceuticals B.V.
13.2.15. BrightPath Biotherapeutics Co., Ltd.
13.2.16. Vaximm AG
13.2.17. Medigene AG
13.2.18. Genocea Biosciences Inc.
13.2.19. Advaxis, Inc.
13.2.20. Nouscom AG
14. Strategic Recommendations
15. About Us & Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook